Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2007-03-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral administration of escitalopram during 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MADRS-score \> 25
* Age: 18-65 yrs
* Medication-free or anti-depressant wash-out 7 days (for fluoxetine: 6 weeks)
* Lorazepam 1mg or zolpidem 10mg are allowed
Exclusion Criteria
* Bipolar disorder, following DSM-IV criteria
* Psychotic symptoms
* Substance abuse
* Personality disorder, following DSM-IV criteria
* Cognitive dysfunction due to trauma capitis or dementia
* Diabetes mellitus
* Women without contraceptive protection, with pregnancy or breast feeding
* Pharmacological treatment or ingestion of substance that can influence cerebral perfusion less than a month before inclusion
* IQ below 80
* Conditions not compatible with SPC
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fund for Scientific Research, Flanders, Belgium
OTHER
H. Lundbeck A/S
INDUSTRY
University Hospital, Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital Ghent
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kurt Audenaert, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Ghent
Ghent, , Belgium
AZ Groeninge campus Sint Maarten
Kortrijk, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Website University Hospital Ghent
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006/176
Identifier Type: -
Identifier Source: org_study_id